A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates.
A rapid screening test for antiviral susceptibility to acyclovir and foscarnet was evaluated in 320 herpes simplex virus (HSV) isolates from 197 patients. Of the isolates tested (16% HSV-1, 84% HSV-2), 60% were resistant in vitro to acyclovir and 5% were resistant to foscarnet using the plaque reduction assay. The rapid screening test, requiring only 3 days to yield a preliminary susceptibility result, was highly associated with the results of the plaque reduction assay for acyclovir and foscarnet (P < or = .001 for each) and with the clinical response to antiviral therapy (P < .001, P = .001, respectively).
Safrin
S
S
Department of Medicine, University of California, San Francisco.
Elbeik
T
T
Mills
J
J
D000212:Acyclovir / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D004352:Drug Resistance, Microbial; D005069:Evaluation Studies as Topic; D017245:Foscarnet / Q000494:pharmacology* / Q000627:therapeutic use; D006558:Herpes Genitalis / Q000188:drug therapy / Q000382:microbiology; D006561:Herpes Simplex / Q000188:drug therapy / Q000382:microbiology; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D018258:Herpesvirus 2, Human / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D009500:Neutralization Tests; D012680:Sensitivity and Specificity; D013997:Time Factors; D014709:Vero Cells
D017245:Foscarnet; D000212:Acyclovir